TABLE 5Etanercept efficacy outcomes: uncontrolled follow-up data

TrialType of dataDurationOutcomesEtanercept/placebo
Mease 200078Uncontrolled36 weeksPsARC26/30 (87%)
ACR 2026/30 (87%)
ACR 5019/30 (63%)
ACR 7010/30 (33%)
HAQ% change from baseline: mean (median)CiC
PASI 757/19 (37%)
PASI 5011/19 (58%)
Mease 200452,97,99,105,107,110Uncontrolled12 monthsACR results, etc. only as brief textMaintained as at 24 weeks
TSS mean (SD) annualised rate of progressionAll pts(n = 101) −0.03 (0.87)
+MTX(n = 42) 0.01 (0.81)
−MTX(n = 59) −0.13 (0.91)
24 monthsTSS mean change from baselineEtanercept/etanercept −0.38

Placebo/etanercept 0.50

From: 3, Assessment of clinical effectiveness

Cover of Etanercept, Infliximab and Adalimumab for the Treatment of Psoriatic Arthritis: A Systematic Review and Economic Evaluation
Etanercept, Infliximab and Adalimumab for the Treatment of Psoriatic Arthritis: A Systematic Review and Economic Evaluation.
Health Technology Assessment, No. 15.10.
Rodgers M, Epstein D, Bojke L, et al.
Southampton (UK): NIHR Journals Library; 2011 Feb.
© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.